Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Abwiz Bio Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, meaning each pending matter is being reviewed by a different individual. Despite the involvement of multiple examiners, the portfolio is concentrated within 1 distinct art unit. This suggests that while the personnel vary, the technical evaluation remains within a specialized group at the USPTO. The focus on 1 art unit indicates a consistent technical theme across the 2 pending office actions.
The busiest examiner for this company is RAYMONDA, MATTHEW HAROLD, who is handling 1 pending office action. Since the busiest examiner pending count is 1, the workload is distributed across the 2 distinct examiners. This arrangement requires the applicant to address the specific preferences of 2 different examiners while operating under the standards of 1 art unit. Managing 2 pending office actions in this manner allows the company to receive diverse feedback while maintaining a presence in a specific technical department. The outcome of the portfolio depends on navigating these distinct examiner relationships.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAYMONDA, MATTHEW HAROLD | 1 | 35.7% | +55.0% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683502 | HUMANIZATION, AFFINITY MATURATION, AND OPTIMIZATION METHODS FOR PROTEINS AND ANTIBODIES | RAYMONDA, MATTHEW HAROLD | — |
| 18378125 | ANTI-IGE ANTIBODIES | HOWARD, ZACHARY C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683502 | HUMANIZATION, AFFINITY MATURATION, AND OPTIMIZATION METHODS FOR PROTEINS AND ANTIBODIES | RAYMONDA, MATTHEW HAROLD | — |
| 18378125 | ANTI-IGE ANTIBODIES | HOWARD, ZACHARY C | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18683502 | HUMANIZATION, AFFINITY MATURATION, AND OPTIMIZATION METHODS FOR PROTEINS AND ANTIBODIES | RAYMONDA, MATTHEW HAROLD | — | §102§103§112 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18378125 | ANTI-IGE ANTIBODIES | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | — | Pending | Oct 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial